Kane Biotech Invited to Present at the BioInterface 2007 Conference
WINNIPEG, MANITOBA -- (MARKET WIRE) -- 10/15/07 -- Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, announced today that its Chief Scientific Officer, Dr. Sri Madhyastha, has been invited to make a scientific presentation on the Company's leading biofilm technologies at the BioInterface 2007 Conference on October 31st in San Mateo, California. The presentation will highlight how the Company's lead technologies can be used to prevent hospital-acquired infections and treat chronic wounds.
"Being invited to present at a specialized conference of this caliber is very positive and demonstrates that Kane Biotech is receiving recognition as a leading company in our field of research," stated Gord Froehlich, President and CEO of Kane Biotech.
Kane Biotech's presentation at the conference will detail its two lead technology platforms:
- DispersinB(TM), a novel antibiofilm enzyme that inhibits as well as disperses bacterial biofilms, with applications in medical devices, wound care, oral care and animal health care. Kane is currently developing a DispersinB(TM) based antibiofilm/antimicrobial wound gel for healing chronic wounds, including venous leg and diabetic ulcers.
- PS/CHX, a broad-spectrum antimicrobial/antibiofilm composition comprising FDA-approved protamine sulfate and chlorhexidine, with applications in anti-infective device coatings, oral care, animal health care, and dairy and food processing industries. This technology has been licensed to Harland Medical Systems to develop antimicrobial urinary catheters.
About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the development of products to prevent and disperse microbial biofilms. Biofilms develop when bacteria, and other microorganisms, form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay.
Kane Biotech Inc. uses patent protected technologies based on molecular mechanisms of biofilm formation and dispersal, to develop antibiofilm products that inhibit or disrupt biofilms. The Company has evidence that these technologies have the potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.
Caution Regarding Forward-Looking Information
Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.
These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Kane's early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Kane's filings with Canadian securities regulatory authorities, as well as Kane's ability to anticipate and manage the risks associated with the foregoing. Kane cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Kane's forward-looking statements to make decisions with respect to Kane, investors and others should carefully consider the foregoing factors and other uncertainties and potential events.
These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Kane cannot provide assurance that actual results will be consistent with these forward-looking statements. Kane undertakes no obligation to update or revise any forward-looking statement.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
Contacts: Kane Biotech Inc. Justin Gagnon Investor Relations Professional (204) 478-5602 (204) 453-1314 (FAX) Email: jgagnon@kanebiotech.com Website: www.kanebiotech.com
Released October 15, 2007